
Peritoneal absorption of moxalactam
Author(s) -
Nancy M. Stephens,
Nouhad O. Kronfol,
Berry J. Kline,
Ron E. Polk
Publication year - 1983
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.24.1.39
Subject(s) - moxalactam , liter , peritoneal dialysis , peritonitis , medicine , continuous ambulatory peritoneal dialysis , latamoxef , pharmacokinetics , absorption (acoustics) , chemistry , pharmacology , antibiotics , cephalosporin , biochemistry , physics , acoustics
We evaluated the rate and extent of the systemic absorption of moxalactam given intraperitoneally to patients with peritonitis and end-stage renal disease who were being maintained on continuous ambulatory peritoneal dialysis. Moxalactam was administered at a concentration of 200 mg per 2-liter dialysate for the first dose, followed by 60 mg per 2-liter exchange for 23 1-h exchanges. Moxalactam concentrations in serum (mean +/- standard deviation) were 2.5 +/- 0.9 mg/liter after the first hourly dialysis, increasing to 10.3 +/- 4.8 mg/liter after 24 h of drug administration. Moxalactam levels in serum at 1 h were above the minimal inhibitory concentrations for most gram-negative organisms except Pseudomonas aeruginosa. No adverse effects of the drug were observed.